Monodisperse Protocells for Targeted Cell Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nanoparticle technologies face challenges in achieving specific cell-type interactions in vivo due to the complex interplay of physicochemical properties, leading to inefficient targeting and prolonged non-specific binding, which limits their therapeutic and diagnostic applications.
Innovation Solution
Development of monodisperse mesoporous silica nanoparticles (MSNPs) with controlled size, surface charge, and PEGylation, encapsulated in a lipid bi- or multi-layer, and conjugated with targeting ligands like CD19 or EGFR antibodies, enabling targeted delivery of therapeutic agents to specific cells while minimizing non-specific binding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional nanoparticles are used with basic physicochemical properties, then manufacturing is simpler, but cell-type specific binding is insufficient
Solution Approach 1:
The nanoparticle is divided into distinct functional segments: a core mesoporous silica nanoparticle for structural integrity and cargo loading, a lipid bi-layer membrane for biocompatibility and circulation, and surface-conjugated targeting ligands for specific cell binding. This segmentation allows each component to optimize its function independently while contributing to overall targeting reliability.
Solution Approach 2:
The nanoparticle employs a composite structure combining mesoporous silica core with a lipid bi-layer envelope and surface-conjugated biological ligands. This composite material approach integrates the advantages of each material: silica provides structural stability and cargo capacity, lipid provides biocompatibility and circulation time, while biological ligands provide specific targeting, collectively achieving reliable cell-type specific binding.
2Duration of action of moving object
If nanoparticle size is decreased to improve circulation time, then circulation time increases, but non-specific binding also increases
Solution Approach 1:
The nanoparticle surface exhibits local quality differentiation through PEGylation density gradients and targeted ligand placement. PEG chains are distributed at optimized densities to provide steric stabilization and reduce non-specific binding, while targeting ligands are positioned at specific locations for optimal receptor interaction. This local quality control allows small particles to maintain long circulation times without excessive non-specific binding.
Solution Approach 2:
The nanoparticle employs parameter optimization including controlled particle size (20-200 nm), optimized PEG chain length and density, and controlled ligand-to-particle ratio. These parameter changes create a balance where the particle is small enough for prolonged circulation but surface-modified to minimize non-specific interactions while maximizing specific targeting efficiency.
3Reliability
If targeting ligands are conjugated to nanoparticles, then cell targeting specificity improves, but manufacturing complexity increases
Solution Approach 1:
The mesoporous silica nanoparticle core is pre-synthesized with controlled porosity and surface area before lipid coating and ligand conjugation. This preliminary action creates a standardized platform with defined cargo capacity and surface properties, simplifying subsequent functionalization steps and enabling batch-to-batch consistency in targeting specificity.
Solution Approach 2:
The lipid bi-layer acts as an intermediary between the inorganic silica core and the biological targeting ligands. This intermediary layer provides a biocompatible interface that facilitates controlled ligand conjugation while maintaining particle stability, simplifying the manufacturing process by decoupling core synthesis from surface functionalization.
4Duration of action of moving object
If PEGylation extent is increased to reduce non-specific binding, then circulation time improves, but targeting ligand accessibility decreases
Solution Approach 1:
The nanoparticle employs optimized PEG parameters including chain length (2000-5000 Da), density (5-20% of surface lipids), and architecture (brush vs. mushroom conformation). These parameter changes create sufficient steric protection against non-specific binding while maintaining adequate spacing between PEG chains to allow targeting ligands to access and bind to cell surface receptors effectively.
Solution Approach 2:
The nanoparticle surface exhibits local quality differentiation with PEG chains distributed at optimized densities to provide steric stabilization, while targeting ligands are positioned at specific locations with controlled spacing. This local quality control ensures that PEGylation provides circulation protection without creating a uniform barrier that would block all ligand-receptor interactions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MSNPs exhibit enhanced specificity and prolonged circulation, achieving targeted binding and delivery to cancer cells and other specific cell types, with minimal non-specific interactions, thereby improving the efficacy of therapeutic and diagnostic applications.
Implementation Method 1
monodisperse mesoporous silica nanoparticles (MSNPs), a cargo, and a targeting ligand... encapsulated in a lipid bi- or multi-layer
Implementation Method 2
the lipid bi- or multi-layer is PEGylated... decreased size, neutral or negative zeta (.zeta.) potential, and extent of PEGylation are correlated with increased circulation time
Implementation Method 3
a targeting ligand, e.g., a CD19 targeting ligand, an EGFR targeting ligand or a motorneuron targeting ligand... the targeting ligand is an antibody
Data Source
AI summary
In one aspect, the disclosure provides mesoporous silica nanoparticles (MSNPs), monodisperse populations of MSNPs and related protocells which exhibit cell binding specificity. For example, MSNPs and protocells of the disclosure may be used to target specific delivery of therapeutic agents to CD19 or EGFR expressing cancer cells, or target specific delivery of therapeutic agents to other cell types. Related protocells, pharmaceutical compositions and therapeutic and diagnostic methods are also provided.